| Drug General Information |
| Drug ID |
D0H1OK
|
| Former ID |
DNC007460
|
| Drug Name |
TG-100435
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H25Cl2N5O
|
| Canonical SMILES |
CC1=C2C(=CC(=C1)C3=C(C=CC=C3Cl)Cl)N=NC(=N2)NC4=CC=C(C=C<br />4)OCCN5CCCC5
|
| InChI |
1S/C26H25Cl2N5O/c1-17-15-18(24-21(27)5-4-6-22(24)28)16-23-25(17)30-26(32-31-23)29-19-7-9-20(10-8-19)34-14-13-33-11-2-3-12-33/h4-10,15-16H,2-3,11-14H2,1H3,(H,29,30,32)
|
| InChIKey |
OTTCBLPTHPBEEX-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Fibroblast growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Ephrin type-B receptor 4 |
Target Info |
Inhibitor |
[1]
|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
| Lck tyrosine kinase |
Target Info |
Inhibitor |
[1]
|
| Proto-oncogene c-Abl |
Target Info |
Inhibitor |
[1]
|
| Proto-oncogene tyrosine-protein kinase receptor ret |
Target Info |
Inhibitor |
[1]
|
| Proto-oncogene tyrosine-protein kinase SRC |
Target Info |
Inhibitor |
[1]
|
| Proto-oncogene tyrosine-protein kinase Yes |
Target Info |
Inhibitor |
[1]
|
| Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
Prostate cancer
|
|
Central carbon metabolism in cancerhsa04360:Axon guidancehsa04014:Ras signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancerhsa04064:NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
HTLV-I infection
|
|
Primary immunodeficiencyhsa04012:ErbB signaling pathway
|
|
Cell cycle
|
|
Axon guidance
|
|
Neurotrophin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
MicroRNAs in cancer
|
|
Chronic myeloid leukemia
|
|
Viral myocarditishsa04144:Endocytosis
|
|
Thyroid cancer
|
|
Central carbon metabolism in cancerhsa04012:ErbB signaling pathway
|
|
Chemokine signaling pathway
|
|
Adherens junction
|
|
Tight junction
|
|
Gap junction
|
|
Platelet activation
|
|
GABAergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancerhsa04520:Adherens junction
|
|
Tight junctionhsa04010:MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
Glioma
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
IL1 Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
IL2 Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_17:IL5 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
FGF signaling pathwayP00005:Angiogenesis
|
|
VEGF signaling pathwayP00049:Parkinson disease
|
|
T cell activationP00008:Axon guidance mediated by Slit/RoboP00005:Angiogenesis
|
|
Cadherin signaling pathway
|
|
Integrin signalling pathway
|
|
Parkinson disease
|
|
CCKR signaling map STP00012:Cadherin signaling pathway
|
|
CCKR signaling map STP00005:Angiogenesis
|
|
PDGF signaling pathway
|
|
Pathway Interaction Database
|
FGF signaling pathwayephbfwdpathway:EPHB forward signaling
|
|
EphrinB-EPHB pathway
|
|
Ephrin B reverse signalinghif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY networknfkappabatypicalpathway:Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
TCR signaling in naï
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
Regulation of p38-alpha and p38-beta
|
|
TCR signaling in naï
|
|
Thromboxane A2 receptor signaling
|
|
IL2-mediated signaling events
|
|
CXCR4-mediated signaling events
|
|
Class I PI3K signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
amb2 Integrin signaling
|
|
EPHA forward signaling
|
|
PDGFR-beta signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Ephrin B reverse signaling
|
|
Alpha-synuclein signalingp73pathway:p73 transcription factor network
|
|
ATM pathway
|
|
Regulation of Telomerase
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
p53 pathway
|
|
Regulation of retinoblastoma proteinret_pathway:Signaling events regulated by Ret tyrosine kinase
|
|
Posttranslational regulation of adherens junction stability and dissassemblyendothelinpathway:Endothelins
|
|
Signaling events mediated by PRL
|
|
LPA receptor mediated events
|
|
Atypical NF-kappaB pathway
|
|
Plasma membrane estrogen receptor signaling
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
S1P3 pathway
|
|
EPHB forward signaling
|
|
Nectin adhesion pathway
|
|
CDC42 signaling events
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
Arf6 signaling events
|
|
FAS (CD95) signaling pathway
|
|
Netrin-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Regulation of Androgen receptor activity
|
|
E-cadherin signaling in the nascent adherens junction
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
ErbB2/ErbB3 signaling events
|
|
E-cadherin signaling in keratinocytes
|
|
Nongenotropic Androgen signaling
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Syndecan-2-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
Syndecan-3-mediated signaling events
|
|
Trk receptor signaling mediated by PI3K and PLC-gamma
|
|
EPHA2 forward signaling
|
|
Alpha-synuclein signaling
|
|
FGF signaling pathway
|
|
Alpha4 beta1 integrin signaling events
|
|
Signaling events mediated by focal adhesion kinasewnt_noncanonical_pathway:Noncanonical Wnt signaling pathway
|
|
Signaling events mediated by focal adhesion kinaseptp1bpathway:Signaling events mediated by PTP1B
|
|
Validated targets of C-MYC transcriptional repression
|
|
PDGF receptor signaling network
|
|
Reactome
|
Activated point mutants of FGFR2R-HSA-2682334:EPH-Ephrin signaling
|
|
EPHB-mediated forward signaling
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferationR-HSA-114604:GPVI-mediated activation cascade
|
|
PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
PECAM1 interactions
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
CD28 co-stimulation
|
|
CD28 dependent PI3K/Akt signaling
|
|
CD28 dependent Vav1 pathway
|
|
CTLA4 inhibitory signaling
|
|
PD-1 signaling
|
|
Interleukin-2 signalingR-HSA-2029482:Regulation of actin dynamics for phagocytic cup formation
|
|
CDO in myogenesis
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
HDR through Single Strand Annealing (SSA)
|
|
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-1433559:Regulation of KIT signaling
|
|
FCGR activation
|
|
EPH-Ephrin signaling
|
|
EPH-ephrin mediated repulsion of cells
|
|
Regulation of signaling by CBLR-HSA-1257604:PIP3 activates AKT signaling
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Ectoderm Differentiation
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Cardiac Hypertrophic Response
|
|
Signaling Pathways in Glioblastoma
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
AngiogenesisWP2877:Vitamin D Receptor PathwayWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Cardiac Progenitor Differentiation
|
|
Signaling by VEGF
|
|
AngiogenesisWP61:Notch Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
IL-2 Signaling Pathway
|
|
Inflammatory Response Pathway
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Host Interactions of HIV factors
|
|
PIP3 activates AKT signaling
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
TCR signaling
|
|
Costimulation by the CD28 familyWP2864:Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by Robo receptor
|
|
Myogenesis
|
|
Factors involved in megakaryocyte development and platelet productionWP706:SIDS Susceptibility Pathways
|
|
Dopaminergic NeurogenesisWP673:ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Pregnane X Receptor pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL-3 Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Angiogenesis
|
|
Androgen receptor signaling pathwayWP2713:Signaling by SCF-KIT
|
|
Costimulation by the CD28 familyWP51:Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
Osteoblast Signaling
|
|
Focal Adhesion
|
|
PDGF Pathway
|
|
Signaling by PDGF
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. Epub 2006 Nov 7.Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays. |
|---|
